Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of director share allocations rather than a financial performance report.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document details the allocation of notional Ordinary Shares and American Depositary Shares (ADSs) to Non-Executive Directors for the service period of July 1, 2014, to September 30, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports the allocation of shares at a price of £14.22 per Ordinary Share and $46.31 per ADS.
Important Facts for Investors
- Transaction Type: Allocation of notional shares to Non-Executive Directors.
- Allocation Date: September 30, 2014 (advised October 1, 2014).
- Share Prices: £14.22 per Ordinary Share; $46.31 per ADS.
- Service Period: July 1, 2014, to September 30, 2014.
- Beneficiaries: Includes Sir Christopher Gent, Professor Sir Roy Anderson, Dr Stephanie Burns, Stacey Cartwright, Lynn Elsenhans, Judy Lewent, Sir Deryck Maughan, Dr Daniel Podolsky, Tom de Swaan, Jing Ulrich, and Hans Wijers.